CA2295094A1 - Method of treating heart failure - Google Patents

Method of treating heart failure Download PDF

Info

Publication number
CA2295094A1
CA2295094A1 CA002295094A CA2295094A CA2295094A1 CA 2295094 A1 CA2295094 A1 CA 2295094A1 CA 002295094 A CA002295094 A CA 002295094A CA 2295094 A CA2295094 A CA 2295094A CA 2295094 A1 CA2295094 A1 CA 2295094A1
Authority
CA
Canada
Prior art keywords
adrenergic receptor
dose
heart failure
positive
adrenergic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002295094A
Other languages
English (en)
French (fr)
Inventor
Michael R. Bristow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado Boulder
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2295094A1 publication Critical patent/CA2295094A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002295094A 1997-06-25 1998-06-24 Method of treating heart failure Abandoned CA2295094A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5067497P 1997-06-25 1997-06-25
US60/050,674 1997-06-25
PCT/US1998/013442 WO1998058638A1 (en) 1997-06-25 1998-06-24 Method of treating heart failure

Publications (1)

Publication Number Publication Date
CA2295094A1 true CA2295094A1 (en) 1998-12-30

Family

ID=21966696

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002295094A Abandoned CA2295094A1 (en) 1997-06-25 1998-06-24 Method of treating heart failure

Country Status (6)

Country Link
US (1) US5998458A (cg-RX-API-DMAC7.html)
EP (1) EP1017376A4 (cg-RX-API-DMAC7.html)
JP (1) JP2002508766A (cg-RX-API-DMAC7.html)
AU (1) AU731656B2 (cg-RX-API-DMAC7.html)
CA (1) CA2295094A1 (cg-RX-API-DMAC7.html)
WO (1) WO1998058638A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996024358A1 (en) * 1995-02-10 1996-08-15 G.D. Searle & Co. Use of low dose amount of spironolactone for treatment of cardiovascular disease
AR030414A1 (es) * 2000-04-03 2003-08-20 Astrazeneca Ab Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
SE0002354D0 (sv) * 2000-06-22 2000-06-22 Astrazeneca Ab New formulation
FI20010233A0 (fi) * 2001-02-08 2001-02-08 Orion Corp Menetelmä sydämen vajaatoiminnan hoitoon
FI20011464A0 (fi) 2001-07-04 2001-07-04 Orion Corp Yhdistelmäterapia sydämen vajaatoiminnan hoitoon
US7020521B1 (en) 2002-11-08 2006-03-28 Pacesetter, Inc. Methods and apparatus for detecting and/or monitoring heart failure
JP2007511487A (ja) 2003-11-17 2007-05-10 ノバルティス アクチエンゲゼルシャフト ジペプチジルペプチダーゼiv阻害剤の使用
US20060018970A1 (en) * 2003-12-12 2006-01-26 Myogen, Inc. Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
JP2007530566A (ja) * 2004-03-22 2007-11-01 ミオゲン インコーポレイティッド (r)−エノキシモンスルホキシドおよびpde−iii媒介疾患の治療におけるその使用
EP1737448A1 (en) * 2004-03-22 2007-01-03 Myogen, Inc. (s) - enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
US20060292213A1 (en) * 2004-06-23 2006-12-28 Myogen, Inc. Enoximone formulations and their use in the treatment of PDE-III mediated diseases
CN104644627A (zh) 2004-09-14 2015-05-27 科罗拉多大学董事会 基于基因靶向使用布新洛尔的治疗方法
CA2610022A1 (en) 2005-06-06 2006-12-14 Georgetown University Compositions and methods for lipo modeling
WO2007014029A2 (en) * 2005-07-22 2007-02-01 The Regents Of The University Of Colorado, A Body Corporate Yin yang 1 as a treatment for cardiac hypertrophy and heart failure
WO2011032088A1 (en) 2009-09-11 2011-03-17 Arca Biopharma, Inc. Polymorphisms in the pde3a gene
CN110520116A (zh) * 2017-01-03 2019-11-29 卡尔迪奥克斯尔制药公司 供硝酰化合物的给予方法
EP4092013A1 (en) 2017-06-20 2022-11-23 Imbria Pharmaceuticals, Inc. Compositions and methods for increasing efficiency of cardiac metabolism
US12318382B2 (en) 2018-10-17 2025-06-03 Imbria Pharmaceuticals, Inc. Methods of treating rheumatic diseases using trimetazidine-based compounds
EP3976101A4 (en) 2019-05-31 2023-06-21 Imbria Pharmaceuticals, Inc. FIBROSIS TREATMENT METHODS USING COMPOUNDS THAT PROMOTE GLUCOSE OXIDATION
EP4146215A4 (en) * 2020-05-04 2024-05-01 Imbria Pharmaceuticals, Inc. DOSING METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE354851B (cg-RX-API-DMAC7.html) * 1970-02-18 1973-03-26 Haessle Ab
US4405635A (en) * 1979-06-18 1983-09-20 Merrell Dow Pharmaceuticals Inc. 4-Aroylimidazol-2-ones and their use as pharmaceuticals

Also Published As

Publication number Publication date
WO1998058638A1 (en) 1998-12-30
EP1017376A4 (en) 2002-10-25
EP1017376A1 (en) 2000-07-12
US5998458A (en) 1999-12-07
AU731656B2 (en) 2001-04-05
AU8174098A (en) 1999-01-04
JP2002508766A (ja) 2002-03-19

Similar Documents

Publication Publication Date Title
US5998458A (en) Method of treating heart failure
Lyu et al. Macrophage-mediated regulation of catecholamines in sympathetic neural remodeling after myocardial infarction
Lu et al. Decreased L-type Ca2+ current in cardiac myocytes of type 1 diabetic Akita mice due to reduced phosphatidylinositol 3-kinase signaling
AU2016204445A1 (en) Dosing regimens for the treatment of fabry disease
WO2010131033A1 (en) Perhexiline for use in the treatment of hypertrophic cardiomyopathy (hcm)
US9457017B2 (en) Treatment of heart failure
KR20220119168A (ko) 심장독성을 감소시키기 위한 조성물 및 방법
WO2022232650A1 (en) Methods for reducing agt expression
Thackeray et al. Insulin restores myocardial presynaptic sympathetic neuronal integrity in insulin-resistant diabetic rats
TW202313021A (zh) 作為強心劑之六氫吡啶脲衍生物
Lainchbury et al. Effects of adrenomedullin on load and myocardial performance in normal and heart-failure dogs
WO2009066085A1 (en) Treatment of heart failure with normal ejection fraction
Gheorghiade et al. Combining SERCA2a activation and Na-K ATPase inhibition: a promising new approach to managing acute heart failure syndromes with low cardiac output
Andersson et al. Recovery from left ventricular asynergy in ischemic cardiomyopathy following long-term beta blockade treatment
Kiriazis et al. Chronic activation of the low affinity site of β1‐adrenoceptors stimulates haemodynamics but exacerbates pressure‐overload cardiac remodelling
Stubenitsky et al. Cardiovascular effects of the novel Ca2+‐sensitiser EMD 57033 in pigs at rest and during treadmill exercise
Zakrzeska et al. Positive inotropic and lusitropic effects mediated via the low‐affinity state of β1‐adrenoceptors in pithed rats
EP3124019B1 (en) Substance selected among midodrine, a pharmaceutical salt and the active metabolite thereof, for use in the treatment of obstructive cardiopathy
Molina et al. Alcohol does not modulate the augmented acetylcholine-induced vasodilatory response in hemorrhaged rodents
Kikura et al. New cardiac drugs
Merkus et al. Alterations in endothelial control of the pulmonary circulation in exercising swine with secondary pulmonary hypertension after myocardial infarction
Young et al. Mg2+ efflux from the isolated perfused rabbit heart is mediated by two states of the β1-adrenergic receptor
EA047888B1 (ru) Применение производных пиперидин мочевины в качестве инотропных агентов
Fujimoto et al. Hemodynamic Changes Following Landiolol Initiation in Patients With Critical Illness Who Developed Tachycardia During Dobutamine Infusion: A Retrospective Observational Study
Lomivorotov et al. Perfusion separation challenge

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued